Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Item 7.01 provides no substantive company disclosure in the supplied text.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Item 7.01 provides no substantive company disclosure in the supplied text
- The 8-K content is excluded from incorporation by reference into future Securities Act or Exchange Act filings
Item 8.01 · Other Events
- Daraxonrasib combination showed 92% ORR, 90% six-month PFS, and 100% DCR in 12 response-evaluable PDAC patients
- Efficacy came from heavily pretreated patients, including 70% with liver metastases, supporting potential activity in advanced disease
- No related grade 4 or 5 adverse events or treatment discontinuations; three DLTs occurred at the 250mg dose
- Company plans Phase 3 front-line pancreatic cancer trial, subject to regulatory feedback, creating a major development catalyst
- Zoldonrasib combination produced 52% ORR, 74% six-month PFS, and 96% DCR across 27 evaluable PDAC patients
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.